Adam Feuerstein

Shares of Gilead Sciences, Inc. (NASDAQ: GILD) gained more than 15% after Thursday's market close and the encouraging report from STAT is "good news" although anecdotal, CNBC's Guy Adami said. The report is encouraging from a human point of view as keeping people safe is...

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX), a small-cap biotech that develops small molecules for rare diseases, were trading down by nearly half Tuesday despite a seemingly positive clinical trial readout. What Happened BioCryst announced Tuesday that a Phase 3 study dubbed APeX-...

Shares of neuroscience company Biogen Inc (NASDAQ: BIIB) lost more than 25 percent Thursday morning after the company said it will discontinue an ongoing Alzheimer's drug study. What Happened Biogen and its partner Japan-based Eisai said they will discontinue an ongoing global Phase 3...

Geron Corporation (NASDAQ: GERN) stock is popping Friday without any major news from the company. Traders are speculating the huge jump in share price may have to do with a simple job posting. Geron's stock was trading up 27 percent to $5.13 at time of publication. What Happened? On Friday...

Neurotrope Inc (NASDAQ: NTRP) announced Monday that it has initiated enrollment for a confirmatory Phase 2 study of bryostatin-1 in Alzheimer’s disease. The typically good news of a drug candidate's progress may not be enough to clear the public's memory of Neurotrope. The stock...

On Friday's PreMarket Prep trading show, STAT News senior writer Adam Feuerstein weighed in on the results from Biogen Inc (NASDAQ: BIIB) and Eisai's Alzheimer's therapy candidate BAN2401. While BAN2401 failed to show a significant difference from a placebo in a 12-month Phase 2...

Incyte Corporation (NASDAQ: INCY), a biopharmaceutical company that focuses on developing medications for the treatment of cancer, announced Friday a disappointing update to a phase 3 trial. What Happened Incyte said its experimental therapy called epacadostat failed in a phase 3 trial called...

Shares of Alkermes Plc (NASDAQ: ALKS) lost more than 20 percent early Monday morning after the U.S. Food and Drug Administration said it won't review the company's therapy ALKS-5461. What Happened Alkermes, which mostly focuses on treatments for central nervous system diseases, said...

Omeros Corporation (NASDAQ: OMER), a commercial-stage biopharmaceutical company that mostly focuses on developing therapies for the treatment of complement-mediated diseases and disorders of the central nervous system, saw its stock soar nearly 40 percent Thursday morning. What Happened American...

Proteostasis Therapeutics Inc (NASDAQ: PTI) stock is down more than 25 percent on Tuesday after short seller Kerrisdale Capital revealed a new report and short position in the company. Kerrisdale said on Twitter the “data is terrible” for Proteostasis lead drug candidate PTI-428,...

Novavax, Inc. (NASDAQ: NVAX) popped 31 percent Wednesday evening after management announced the NanoFlu Vaccine demonstrated improved immune responses over alternative flu vaccines. Biotech experts disputed the data’s significance, with STAT News' Adam Feuerstein confessing skepticism. I...

Shares of Pain Therapeutics, Inc. (NASDAQ: PTIE) soared higher by more than 150 percent Tuesday after the company announced encouraging results from a study involving its late-stage drug candidate, REMOXY. What You Need To Know Pain Therapeutics said that REMOXY, a drug candidate intended to be...

It's that time of the year again. As we head in 2018, it's time to reassess your financial strategy and who you follow and where you are getting information plays an important role in your decision making, subconsciously or not. Twitter Inc (NYSE: TWTR) has emerged as a critical platform...

JPMorgan Chase & Co. (NYSE: JPM) is taking heat from investors, reporters and biotech enthusiasts this week after the company decided to restrict access to its small breakout sessions following presentations at its upcoming 36th Annual Healthcare Conference in San Francisco Jan. 8-11. “...

Spark Therapeutics Inc (NASDAQ: ONCE) saw its name transition from Wall Street headlines to Main Street headlines after a U.S. Food and Drug Administration voted favorably on the company's therapy. Spark develops a gene therapy treatment called Luxturna for a rare inherited blindness disease,...